Definium Therapeutics (NASDAQ:DFTX) Stock Price Down 6.2% – Here’s Why

Posted by Geri Gentry on Aug 11th, 2026

Definium Therapeutics, Inc. (NASDAQ:DFTX – Get Free Report) fell 6.2% during mid-day trading on Tuesday . The stock traded as low as $41.81 and last traded at $42.34. 600,915 shares changed hands during mid-day trading, a decline of 73% from the average daily volume of 2,245,691 shares. The stock had previously closed at $45.15.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on DFTX shares. Needham & Company LLC upped their price target on shares of Definium Therapeutics from $38.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, June 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Definium Therapeutics in a report on Friday, July 17th. Wells Fargo & Company began coverage on Definium Therapeutics in a research note on Monday, July 27th. They set an “overweight” rating and a $68.00 price objective for the company. Canaccord Genuity Group set a $58.00 target price on Definium Therapeutics and gave the company a “buy” rating in a report on Tuesday, June 30th. Finally, Oppenheimer set a $60.00 target price on Definium Therapeutics and gave the company an “outperform” rating in a research report on Monday, June 22nd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $55.00.

Read Our Latest Stock Analysis on Definium Therapeutics

Definium Therapeutics Stock Performance

The company has a current ratio of 6.95, a quick ratio of 6.95 and a debt-to-equity ratio of 0.04. The stock’s fifty day simple moving average is $38.32 and its 200 day simple moving average is $26.16. The company has a market cap of $4.11 billion, a price-to-earnings ratio of -12.01 and a beta of 2.23.

Definium Therapeutics (NASDAQ:DFTX – Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.89). As a group, analysts anticipate that Definium Therapeutics, Inc. will post -2.27 earnings per share for the current year.

Insider Buying and Selling

In other Definium Therapeutics news, insider Matthew T. Wiley sold 2,867 shares of the company’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $129,101.01. Following the completion of the sale, the insider directly owned 174,633 shares in the company, valued at $7,863,723.99. This represents a 1.62% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Robert Barrow sold 29,208 shares of the firm’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $1,315,236.24. Following the completion of the sale, the chief executive officer directly owned 1,098,246 shares of the company’s stock, valued at $49,454,017.38. This trade represents a 2.59% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 48,096 shares of company stock worth $2,165,763. 2.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Commodore Capital LP grew its holdings in shares of Definium Therapeutics by 10.5% in the second quarter. Commodore Capital LP now owns 5,000,000 shares of the company’s stock valued at $32,450,000 after purchasing an additional 475,000 shares during the period. Orbimed Advisors LLC acquired a new position in Definium Therapeutics in the 3rd quarter valued at about $4,337,000. Two Sigma Investments LP grew its stake in shares of Definium Therapeutics by 424.9% in the 3rd quarter. Two Sigma Investments LP now owns 296,443 shares of the company’s stock valued at $3,495,000 after buying an additional 239,965 shares during the period. Vanguard Group Inc. grew its stake in shares of Definium Therapeutics by 11.0% in the 3rd quarter. Vanguard Group Inc. now owns 2,012,874 shares of the company’s stock valued at $23,732,000 after buying an additional 198,878 shares during the period. Finally, Millennium Management LLC grew its stake in shares of Definium Therapeutics by 62.6% in the 3rd quarter. Millennium Management LLC now owns 298,205 shares of the company’s stock valued at $3,516,000 after buying an additional 114,805 shares during the period. Institutional investors and hedge funds own 27.91% of the company’s stock.

Definium Therapeutics Company Profile

(Get Free Report)

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.